LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Shanghai Jiao Tong University
Shangai, ChinaPublicaciones en colaboración con investigadores/as de Shanghai Jiao Tong University (6)
2023
-
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
Journal of Thoracic Oncology, Vol. 18, Núm. 2, pp. 204-222
2021
-
Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273] (ESMO Open (2021) 6(5), (S2059702921002350), (10.1016/j.esmoop.2021.100273))
ESMO Open
-
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 2, pp. 198-211
-
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
ESMO Open, Vol. 6, Núm. 5
2019
-
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
Lung Cancer, Vol. 132, pp. 126-131
2017
-
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
Annals of Oncology, Vol. 28, Núm. 2, pp. 270-277